Abbott announced that its fourth-generation MitraClip device, MitraClip G4, was approved by the US Food and Drug Administration on July 15, 2019, to treat mitral regurgitation (MR) in a wider population of patients. The MitraClip G4 include new clip sizes and an enhanced leaflet grasping feature
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Cardiac
July 16, 2019
Aortic valve repair is complex, and techniques must be tailored to the pathology. With this in mind, the author summarizes his core philosophy on aortic valve repair in 10 points:
July 16, 2019
The authors present their experience with the Memo 4D ring by LivaNova in complex mitral valve repair.
July 12, 2019
Investigators reported the distribution of thoracic aortic growth in smokers based on longitudinal data of current and ex-smokers aged 50-70 years from the Danish Lung Cancer Screening Trial.
July 11, 2019
An important update on the evolving landscape of surgery for atrial fibrillation.
July 11, 2019
Filmed at the 2019 STS Annual Meeting in San Diego, California, Mara Antonoff of the University of Texas MD Anderson Cancer Center moderates a discussion on building a practice early in one's career.
July 11, 2019
Later this year, AATS will launch two new open access journals, JTCVS Open and JTCVS Techniques, to provide authors with additional options to publish high-quality information of importance to thoracic and cardiovascular surgeons.
July 10, 2019
Tirone David's experience on his operation, with interesting data on the durability of the re-implantation.
July 10, 2019
Hamandi and colleagues reviewed outcomes for 95 patients who underwent isolated tricuspid valve (TV) surgery between 2007 and 2017 at their institution. For 41% of patients, the procedure was reoperative, following either prior coronary artery bypass grafting or prior valve surgery. Valve repair was performed in over 70% of patients.
July 9, 2019
Transcatheter aortic valve replacement (TAVR) is expanding to younger patients, but the feasibility of TAVR in failing transcatheter aortic valves (TAV) remains unknown.